Evolving management of optic neuritis and multiple sclerosis

被引:115
作者
Arnold, AC [1 ]
机构
[1] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA
关键词
D O I
10.1016/j.ajo.2005.01.031
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To review the relation of optic neuritis to multiple sclerosis (MS) and the indications, modalities, and results of therapy for optic neuritis, for both visual and general neurologic function. DESIGN: Literature review and author's experience. METHODS: Analysis of both laboratory and clinical evidence supporting the use of corticosteroids, immuno-modulation agents, and other modalities in the treatment of optic neuritis and MS. RESULTS: Although treatment of optic neuritis with corticosteroids may hasten visual recovery to a minor degree, it has no long-term beneficial effect on visual outcome. Optic neuritis is frequently the initial manifestation of multiple sclerosis. The risk of later development of clinically definite MS (CDMS) correlates with white matter demyelinative lesions on magnetic resonance imaging (MRI). The role of corticosteroid therapy alone in reducing the risk of subsequent MS is unclear, but recent studies suggest that the combination of immunomodulation agents (IMAs) and corticosteroids significantly reduces the later development of MS. Current research indicates that, contrary to previous doctrine, axonal damage is an early finding in MS. CONCLUSIONS: The risk of MS after optic neuritis may be predicted. The use of corticosteroids and IMAs, particularly in those at substantial risk, reduces the frequency and severity of developing CDMS. Earlier, more aggressive therapy in optic neuritis may be proven to reduce permanent axonal injury and progressive disability in MS. (c) 2005 by Elsevier Inc. All rights reserved.
引用
收藏
页码:1101 / 1108
页数:8
相关论文
共 54 条
[21]   Prognostic value of magnetic resonance imaging in monosymptomatic optic neuritis [J].
Dunker, S ;
Wiegand, W .
OPHTHALMOLOGY, 1996, 103 (11) :1768-1773
[22]  
DUQUETTE P, 1995, NEUROLOGY, V45, P1277
[23]  
FARRIS BK, 1990, OPHTHALMOLOGY, V97, P339
[24]   Axonal damage in acute multiple sclerosis lesions [J].
Ferguson, B ;
Matyszak, MK ;
Esiri, MM ;
Perry, VH .
BRAIN, 1997, 120 :393-399
[25]   A REASSESSMENT OF THE RISK OF MULTIPLE-SCLEROSIS DEVELOPING IN PATIENTS WITH OPTIC NEURITIS AFTER EXTENDED FOLLOW-UP [J].
FRANCIS, DA ;
COMPSTON, DAS ;
BATCHELOR, JR ;
MCDONALD, WI .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1987, 50 (06) :758-765
[26]  
Francis G, 2001, NEUROLOGY, V56, P1628
[27]  
Gal RL, 2004, ARCH NEUROL-CHICAGO, V61, P1386
[28]   Immunomodulatory agents for the treatment of relapsing multiple sclerosis [J].
Galetta, SL ;
Markowitz, C ;
Lee, AG .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (19) :2161-2169
[29]   Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests [J].
Ghezzi, A ;
Martinelli, V ;
Torri, V ;
Zaffaroni, M ;
Rodegher, M ;
Comi, G ;
Zibetti, A ;
Canal, N .
JOURNAL OF NEUROLOGY, 1999, 246 (09) :770-775
[30]   Perils and pitfalls in the interpretation of clinical trials: A reflection on the recent experience in multiple sclerosis [J].
Goodin, DS .
NEUROEPIDEMIOLOGY, 1999, 18 (02) :53-63